ORABLOC (articaine hydrochloride and epinephrine bitartrate) by Pierre Fabre is anesthetic. First approved in 2010.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
ORABLOC is a local anesthetic combination of articaine hydrochloride and epinephrine bitartrate administered by injection for dental and oral procedures. It works by blocking nerve impulse generation and conduction, with epinephrine acting as a vasoconstrictor to prolong anesthetic effect by slowing systemic absorption. The product is indicated for infiltration anesthesia and nerve blocks in oral surgical contexts.
Product approaching loss of exclusivity with moderate competitive pressure (30); brand teams will focus on retention and specialty positioning within dental/oral anesthesia market.
anesthetic. Local anesthetics block the generation and conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential. In general, the progression…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
274 linked positions indicate active hiring across Pierre Fabre's organization, with emphasis on R&D and Commercial teams supporting ORABLOC and portfolio. Roles span technical infrastructure, data science, and category management, suggesting digital transformation and supply chain optimization initiatives alongside commercial execution.
Worked on ORABLOC at Pierre Fabre? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
274 open roles linked to this drug